Key Highlights

• Ocugen received provisional approval and priority designation for OCU400 in The Bahamas, with potential patient enrollment as early as year-end 2026.

• The company executed an exclusive OCU400 license agreement for the Middle East and North Africa with Roots Pharmaceutical, its second regional deal.

• Dosing began in the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy, a 240-patient global study.

• Cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million, with expected runway into 2028.

Ocugen, Inc.(NASDAQ:OCGN), a biotechnology company focused on gene therapies for blindness diseases, provided its third-quarter 2026 Business update alongside financial results, reporting progress across all three of its late-stage modifier gene therapy programs. With Phase 3 topline data for its lead candidate expected in early 2027 and new regional licensing agreements in place, the company is advancing on multiple fronts toward potential regulatory submissions and commercial readiness.

OCU400 Nears Phase 3 Readout

OCU400, Ocugen's lead gene therapy candidate for retinitis pigmentosa (RP), remains the program closest to a pivotal data readout. Top-line results from the 140-patient Phase 3 liMeliGhT trial are expected in Q1 2027, with a Biologics License Application (BLA) submission planned to follow. The company completed Process Performance Qualification batches to support both the regulatory filing and eventual commercial supply.

During the quarter, Ocugen secured provisional approval and priority designation for OCU400 from the Longevity and Regenerative Therapies (LARTA) Board in The Bahamas. The company has partnered with the Global Alliance for Regenerative Medicine (GARM) to manage patient care in the region, with site readiness progressing and the possibility of patient enrollment by year-end 2026.

Ocugen also completed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical. Under the terms, Ocugen is eligible for up to $4 million in combined upfront and initial development milestone payments, up to $255 million in potential sales milestones, and a 22% Royalty on net sales. This marks the company's second regional licensing agreement, following a deal with Kwangdong Pharmaceutical in South Korea.

Geographic Atrophy Program Enters Phase 3

Ocugen announced the first patient dosed in ArMaDa3, its 240-patient global Phase 3 trial for OCU410 in geographic atrophy (GA). The trial randomizes patients on a 2:1 basis to a single subretinal injection of OCU410 or an untreated control arm, with the primary endpoint measuring GA lesion growth over 12 months. Study sites span the United States, Canada, and Europe.

Twelve-month Phase 2 ArMaDa2 data were presented at three scientific conferences during the period, including two podium presentations at AAO 2026, providing additional clinical evidence to support the Phase 3 program.

Stargardt Disease Program Advances

Topline data from the Phase 2/3 pivotal confirmatory trial for OCU410ST in Stargardt disease, which enrolled 63 subjects, are anticipated in Q2 2027. A BLA submission is planned to follow the data readout.

Financial Overview

Ocugen ended Q3 2026 with $84.6 million in cash, cash equivalents, restricted cash, and short-term investments, which the company expects to support operations into 2028. Total operating expenses for the quarter were $19.7 million. The company had 339.3 million shares of common stock outstanding as of September 30, 2026.

To support its expanding international development efforts, Ocugen named Jolanda Crombach as General Manager of its newly established European affiliate in Amsterdam. Crombach previously served as Managing Director at Moderna Netherlands and held Leadership positions at MSD and Pfizer.

The Road Ahead

Ocugen's near-term trajectory hinges on several clinical and regulatory milestones spanning its three-program portfolio. The OCU400 Phase 3 readout in early 2027 represents the most immediate potential catalyst, while the initiation of the ArMaDa3 trial for geographic atrophy expands the company's addressable market. With licensing agreements in place across multiple regions and a cash runway extending into 2028, the company is positioning itself for what could be a defining period in its development timeline.